Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Amadeus Fire Aktie legt vor Halbjahresbericht kräftig zu (Investing.com DE) +++ AMADEUS FIRE Aktie -24,63%

REGENERON Aktie

 >REGENERON Aktienkurs 
605.5 EUR    +3.2%    (TradegateBSX)
Ask: 603.1 EUR / 100 Stück
Bid: 601.8 EUR / 100 Stück
Tagesumsatz: 83 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
REGENERON Aktie über LYNX handeln
>REGENERON Performance
1 Woche: +0,3%
1 Monat: +6,2%
3 Monate: -7,1%
6 Monate: -7,8%
1 Jahr: +22,6%
laufendes Jahr: -10,8%
>REGENERON Aktie
Name:  REGENERON PHARMACEUTICALS
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US75886F1075 / 881535
Symbol/ Ticker:  RGO (Frankfurt) / REGN (NASDAQ)
Kürzel:  FRA:RGO, ETR:RGO, RGO:GR, NASDAQ:REGN
Index:  S&P500, Nasdaq100
Webseite:  https://www.regeneron.com..
Profil:  Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on discovering, developing, and commercializing medicines for serious diseases across eye care, immunology, oncology, cardiovascular health, and inflammation. Its current portfolio in..
>Volltext..
Marktkapitalisierung:  60481.08 Mio. EUR
Unternehmenswert:  55237.96 Mio. EUR
Umsatz:  13120.28 Mio. EUR
EBITDA:  3854.23 Mio. EUR
Nettogewinn:  3889.93 Mio. EUR
Gewinn je Aktie:  37.4 EUR
Schulden:  2379.83 Mio. EUR
Liquide Mittel:  2612.34 Mio. EUR
Operativer Cashflow:  4408.16 Mio. EUR
Bargeldquote:  1.72
Umsatzwachstum:  -0.82%
Gewinnwachstum:  -7.94%
Dividende je Aktie:  3.12 EUR
Dividendenrendite:  0.55%
Dividendenschätzung:  0.57%
Div. Historie:  20.05.26 - 0.808306€
20.02.26 - 0.798906€
>weitere anzeigen...
Insiderhandel:  1 Insider verkaufte innerhalb der letzten 30 Tage Aktien im Wert von 114.305 Euro.
Suchwörter:  REGENERON
Letzte Datenerhebung:  28.07.26
>REGENERON Kennzahlen
Aktien/ Unternehmen:
Aktien: 103.02 Mio. St.
Frei handelbar: 97.98%
Leerverk. Aktien: 3.4%
Rückkaufquote: 3.57%
Mitarbeiter: 15410
Umsatz/Mitarb.: 0.82 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: 27.01%
Bewertung:
KGV: 16.03
KGV lG: 14.15
KUV: 4.65
KBV: 2.2
PEG-Ratio: 3.51
EV/EBITDA: 14.33
Rentabilität:
Bruttomarge: 80.93%
Gewinnmarge: 29.65%
Operative Marge: 25.76%
Managementeffizenz:
Gesamtkaprendite: 11.28%
Eigenkaprendite: 14.55%
>REGENERON Peer Group
Gesundheit, Antikörper- Behandlung, Augenmedizin/ Sehhilfen, Rheuma- Behandlung
 
28.07.26 - 16:18
 Regeneron Pharmaceuticals, Inc. (REGN) Faces Securities Class Action Amid Disclosures About Key Trial′s Protocol and Ultimate Failure - HBSS (PR Newswire)
 
SAN FRANCISCO, July 28, 2026 /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ: REGN) faces a securities class action lawsuit after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat patients with melanoma. The news that the trial failed drove......
28.07.26 - 12:42
 REGN Class Reminder: Regeneron Investors are Reminded of the Upcoming September 14 Deadline in the Filed Securities Fraud Class Action to Recover Losses (PR Newswire)
 
A securities fraud class action lawsuit has been filed on behalf of Regeneron investors after its stock plummeted almost 10% because Regeneron allegedly misled investors regarding the success of its Phase III Fianlimab-Libtayo clinical trial. NEW YORK, July 28, 2026 /PRNewswire/ --......
27.07.26 - 23:39
 Regeneron Pharmaceuticals (NASDAQ: REGN) Investors Who Suffered Losses May Be Eligible to Participate in the Securities Class Action; Contact Robbins LLP for Information About Recovering Your Losses (PR Newswire)
 
Lead Plaintiff Deadline: September 14, 2026 SAN DIEGO, July 27, 2026 /PRNewswire/ -- Robbins LLP reminds investors that a securities class action has been filed on behalf of investors who purchased or otherwise acquired Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between......
27.07.26 - 15:36
 INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. (REGN) Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit (PR Newswire)
 
SAN FRANCISCO, July 27, 2026 /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ: REGN) faces a securities class action lawsuit after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat patients with melanoma. The news that the trial failed drove......
24.07.26 - 19:42
 The Scientist With 1,000 Patents Fueling a Drug Powerhouse (WSJ EN)
 
At Regeneron, George Yancopoulos is the rare scientist and executive who drives growth with discoveries instead of acquisitions....
24.07.26 - 14:03
 Regeneron Pharmaceuticals, Inc. (REGN) Faces Securities Class Action Amid Disclosures About Key Trial′s Protocol and Ultimate Failure - HBSS (PR Newswire)
 
SAN FRANCISCO, July 24, 2026 /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ: REGN) faces a securities class action lawsuit after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat patients with melanoma. The news that the trial failed drove......
23.07.26 - 16:18
 SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN (PR Newswire)
 
Regeneron's clinical-trial risk disclosures are under scrutiny after allegations that the Company minimized Phase III Fianlimab-Libtayo statistical and protocol risks, including potential impact of FDA Otptimus-related amendments on progression-free survival analysis. NEW YORK, July 23,......
23.07.26 - 15:06
 INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. (REGN) Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit (PR Newswire)
 
SAN FRANCISCO, July 23, 2026 /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ: REGN) faces a securities class action lawsuit after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat patients with melanoma. The news that the trial failed drove......
22.07.26 - 18:18
 Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm (PR Newswire)
 
NEW YORK, July 22, 2026 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and certain of its officers. This lawsuit seeks to......
22.07.26 - 13:03
 John Overton High School student receives Humane Science Award from National Anti-Vivisection Society (PR Newswire)
 
Parker Nunnery one of five young scientists from across the world to receive $3,000 prize at 2026 Regeneron International Science and Engineering Fair NASHVILLE, Tenn., July 22, 2026 /PRNewswire/ -- Parker Nunnery, a 2026 John Overton High School graduate, was one of just five recipients......
22.07.26 - 01:09
 Regeneron Pharmaceuticals, Inc. (REGN) Faces Securities Class Action Amid Disclosures About Key Trial′s Protocol and Ultimate Failure - HBSS (PR Newswire)
 
SAN FRANCISCO, July 21, 2026 /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ: REGN) faces a securities class action lawsuit after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat patients with melanoma. The news that the trial failed drove......
21.07.26 - 16:12
 The Gross Law Firm Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 14, 2026 - REGN (PR Newswire)
 
NEW YORK, July 21, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Shareholders who purchased shares of REGN during the class period listed are encouraged to contact the firm regarding possible lead......
20.07.26 - 13:33
 Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload (PR Newswire)
 
Biohaven also announces new clinical supply agreement with Regeneron to evaluate BHV-1530 in combination with cemiplimab (Libtayo®) Early clinical activity observed: Phase 1 dose-escalation data show early tumor reductions in patients with Fibroblast Growth Factor Receptor (FGFR)3-altered......
20.07.26 - 09:03
 Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REGN (PR Newswire)
 
LOS ANGELES, July 20, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ: REGN) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated......
20.07.26 - 09:03
 REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm (PR Newswire)
 
LOS ANGELES, July 20, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ: REGN) for violations of §§10(b) and 20(a) of the......
17.07.26 - 16:06
 REGN Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Filed Against Regeneron Pharmaceuticals, Inc. (PR Newswire)
 
SAN DIEGO, July 17, 2026 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Regeneron Therapeutics, Inc. (NASDAQ: REGN) from August 1, 2025 to May 15, 2026. Regeneron is a pharmaceutical company that......
08.07.26 - 02:01
 Insiderhandel: Aufsichtsrat verkauft Aktien von Regeneron Pharmaceuticals im Wert von 130030 USD (Insiderkauf)
 
Ryan, Arthur F. - Aufsichtsrat - Tag der Transaktion: 2026-07-02...
07.07.26 - 19:45
 Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report? (Zacks)
 
Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report....
07.07.26 - 16:18
 Regeneron Pharmaceuticals Aktie: HSBC senkt Kursziel deutlich auf 800 USD - Therapeutika bleiben Favorit (Aktiencheck)
 
London (www.aktiencheck.de) - Regeneron Pharmaceuticals-Aktienanalyse von HSBC: Die Analysten von HSBC haben das Kursziel für die Aktie von Regeneron Pharmaceuticals Inc. (ISIN: US75886F1075, WKN: 881535, Ticker-Symbol: RGO, NASDAQ-Symbol: REGN) von 990 USD auf 800 USD gesenkt und das Rating "buy" bestätigt. [mehr]...
06.07.26 - 13:54
 Regeneron Pharmaceuticals Aktie: Biotech-Chance oder Warnsignal? (Aktiencheck)
 
New York (www.aktiencheck.de) - Regeneron Pharmaceuticals-Aktienanalyse von Cantor Fitzgerald: Der Analyst Carter Gould vom Analysehaus Cantor Fitzgerald habe das Kursziel für die Aktie von Regeneron Pharmaceuticals Inc. (ISIN: US75886F1075, WKN: 881535, Ticker-Symbol: RGO, NASDAQ-Symbol: REGN) von 785 auf 750 USD gesenkt und das Rating "overweight" bestätigt. [mehr]...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Respekt vor den Fakten. Gefühl für das Wichtige. Kraft zur Unabhängigkeit. - Nomen Nescio
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!